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BACKGROUND: Although tobacco- and alcohol-associated head and neck cancers are declining in the developed world, potentially
human papillomavirus (HPV)-associated oropharnygeal cancers are increasing.
METHODS: We analysed oropharyngeal and oral cavity cancer rates in Australia in 1982–2005. Cancers from the oropharynx (base of
tongue, tonsil and other specific oropharyngeal sites) were classified as potentially HPV associated (n¼8844); cancers in other oral
cavity and oropharyngeal sites not previously associated with HPV were classified as comparison (n¼28379).
RESULTS: In 2000–2005, an average of 219, 159 and 110 cancers of the tonsil, base of tongue and other oropharyngeal sites were
diagnosed annually, with incidences of 1.09 (95% CI: 1.03, 1.15), 0.79 (95% CI: 0.74, 0.84) and 0.55 (95% CI: 0.50, 0.59) per 100000,
respectively. An average of 1242 comparison cancers were diagnosed annually (6.17 (95% CI: 6.03, 6.31) per 100000). In
1982–2005, there were significant annual increases in tonsil (1.39% (95% CI: 0.88, 1.92%)) and base of tongue cancers in males
(3.02% (95% CI: 2.27, 3.78%)) and base of tongue cancer in females (3.45% (95% CI: 2.21, 4.70%)). There was a significant decrease
in comparison cancers in men ( 1.69% (95% CI:  1.96,  1.42%)), but not in females.
CONCLUSION: Potentially HPV-associated oropharyngeal cancer in Australia is increasing; the impact of HPV vaccination on these
cancers should be monitored.
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Cancers of the head and neck arising from the mucosa lining the
oral cavity, oropharynx, hypopharynx, larynx, sinonasal tract and
nasopharynx (Marur et al, 2010) represent a considerable burden
worldwide, being the fifth most common cancer in 2008 (IARC,
2010). Tobacco use and alcohol consumption are known risk
factors for many of these cancers (Blot et al, 1988; Franceschi et al,
1990; Hashibe et al, 2007), but more recently human papilloma-
virus (HPV) infection has been found to be strongly associated
with oropharyngeal cancer (Gillison et al, 2000; Herrero et al, 2003;
Gillison, 2004).
There are epidemiological differences between HPV-DNA-
positive and HPV-DNA-negative head and neck cancers, HPV-
DNA-positive cancers are associated with younger age and higher
numbers of sexual partners, but are less associated with tobacco
smoking compared with HPV-DNA-negative cancers (Chaturvedi
et al, 2008; Gillison et al, 2008; Heck et al, 2010). The proportion of
head and neck cancers that are HPV DNA positive varies
considerably. The most recent systematic review found that the
average HPV DNA positivity was 35.6% for oropharyngeal cancer
and 23.5% for oral cavity cancer (Kreimer et al, 2005). However,
this review classified all tongue cancers as oral cavity cancers and
did not differentiate between base of tongue (classified anatomi-
cally as an oropharyngeal site) and surface or border of tongue
(classified anatomically as an oral cavity site; Kreimer et al, 2005).
As HPV DNA positivity varies by site and is highest in the tonsil
and base of tongue (Herrero et al, 2003; Gillison, 2007), this review
may have underestimated oropharyngeal cancer HPV DNA
positivity and overestimated oral cavity cancer positivity. This
review also showed that there is substantial variation in the
proportion of HPV-DNA-positive cancers by country and study;
part of this may be because of the different distributions of risk
factors other than HPV infection such as tobacco consumption and
also to the accuracy of cancer site classification.
Although the incidence of head and neck cancers associated
with tobacco and alcohol consumption has decreased considerably
in the developed world, that of oropharnygeal cancers has
increased (Ryerson et al, 2008; Chaturvedi et al, 2009). Given the
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yaetiological role of HPV in some oropharyngeal cancers, it is
possible that the incidence of these cancers may decline after HPV
vaccination. In this report, we examine the incidence of
oropharyngeal and oral cavity cancer in Australia from 1982 to
2005.
METHODS
Cancer incidence data were obtained from the National Cancer
Statistics Clearing House database (NCSCH), which was estab-
lished in 1986 to co-ordinate cancer statistics nationally at the
Australian Institute of Health and Welfare. It collates data
provided from the eight Australian State and Territory Cancer
Registries, covering the entire Australian population.
Cancer cases were coded according to the version of the
International Classification of Disease for Oncology (ICD-O) that
was in use at the time of diagnosis. The third edition of the ICD-O
(ICD-O-3) was used for diagnosis years from 2001 onwards; the
data using the previous editions were converted to ICD-O-3 codes
using pre-defined and standard mapping algorithms. The Regis-
tries use the International Agency for Research on Cancer (IARC)
and the International Association of Cancer Registries rules to
code all cancer diagnoses (Fritz et al, 2000; IARC, 2004). For the
purpose of this analysis, and consistent with other published
similar studies (Ryerson et al, 2008), cancers arising in the
following oropharyngeal sites were classified as ‘potentially HPV
associated’ – base of tongue and lingual tonsil, tonsil and
Waldeyer’s ring and other specific sites within the oropharynx.
Cancers in other oral cavity and oropharyngeal sites that have not
been previously associated with HPV infection were also included
in the analysis and classified as ‘comparison’ site cancers (Ryerson
et al, 2008). (Table 1) All analyses were restricted to squamous cell
histologies (ICD-O-3 codes 8500 to 8076, 8078, 8083, 8084 and
8094). The number of cancer cases diagnosed between 1 January
1982 and 31 December 2005 were obtained stratified by age group
(five year age groups), sex, ICD-O code and histology.
Statistical analyses
Age-specific incidence rates were calculated by year of cancer
diagnosis and by birth cohort. Birth cohorts were generated by
subtracting the midpoint of attained age from the year of cancer
notification, and regrouped in 5-year birth cohort periods.
Incidence rates were age standardised to the Australian 2001
standard population (Australian Bureau of Statistics, 2008), and
their trends by year of cancer diagnosis were analysed using
generalised linear models with a logarithmic link function and
expressed as annual percentage change in incidence. Goodness of
fit of the model was checked using the Pearson statistic and the
reported models fit the data well (P40.990 for all models). Trends
in mean age over the study period were examined using linear
regression models. Model fit was checked using standard
diagnostic plots and the normal distribution of residuals was
confirmed using the Shapiro–Wilks test.
All analysis was undertaken using Stata Version 11.0 (StataCorp,
2010).
RESULTS
During the study period from 1982 to 2005, 8844 cases
of potentially HPV-associated oropharyngeal cancers were
Table 1 Age standardised incidence rates of oropharyngeal and oral cavity cancers in Australia
a
Potentially HPV-associated cancers
Tonsil
b Base of tongue and lingual tonsil
c Other oropharynx
d Comparison cancers
e
Time Count (%) Rate
f 95% CI Count (%) Rate 95% CI Count (%) Rate 95% CI Count (%) Rate 95% CI
1982–2005
Total 3898 (100) 0.98 0.95–1.01 2610 (100) 0.66 0.63–0.68 2336 (100) 0.58 0.56–0.61 28379 (100) 7.12 7.04–7.21
Females 925 (23.7) 0.45 0.42–0.48 623 (23.9) 0.30 0.27–0.32 493 (21.1) 0.23 0.21–0.25 6591 (23.2) 3.11 3.03–3.18
Males 2973 (76.3) 1.54 1.49–1.60 1987 (76.1) 1.04 0.99–1.08 1843 (78.9) 0.97 0.92–1.01 21788 (76.8) 11.58 11.42–11.73
2000–2005
Total 1315 (100) 1.09 1.03–1.15 954 (100) 0.79 0.74–0.84 661 (100) 0.55 0.50–0.59 7453 (100) 6.17 6.03–6.31
Females 282 (21.4) 0.46 0.40–0.51 227 (23.8) 0.36 0.31–0.41 128 (19.3) 0.20 0.16–0.23 1866 (25.0) 2.89 2.76–3.03
Males 1033 (78.6) 1.74 1.64–1.85 727 (76.2) 1.23 1.14–1.32 533 (80.6) 0.91 0.84–0.99 5587 (75.0) 9.75 9.5–10.01
1994–1999
Total 993 (100) 0.95 0.89–1.01 786 (100) 0.75 0.70–0.80 650 (100) 0.62 0.57–0.67 7296 (100) 6.99 6.83–7.15
Females 236 (23.8) 0.44 0.38–0.49 190 (24.2) 0.35 0.30–0.39 149 (22.9) 0.27 0.22–0.31 1803 (24.7) 3.23 3.08–3.38
Males 757 (76.2) 1.50 1.39–1.61 596 (75.8) 1.19 1.09–1.28 501 (77.1) 1.02 0.93–1.11 5493 (75.3) 11.16 10.86–11.45
1988–1993
Total 833 (100) 0.90 0.84–0.97 518 (100) 0.57 0.52–0.62 558 (100) 0.60 0.55–0.65 7114 (100) 7.70 7.52–7.88
Females 202 (24.3) 0.42 0.36–0.48 128 (24.7) 0.26 0.22–0.31 122 (21.9) 0.24 0.20–0.29 1559 (21.9) 3.18 3.02–3.33
Males 631 (75.7) 1.42 1.31–1.54 390 (75.3) 0.90 0.80–0.99 436 (78.1) 0.98 0.88–1.07 5555 (78.1) 12.72 12.37–13.06
1982–1987
Total 757 (100) 0.92 0.85–0.98 352 (100) 0.43 0.39–0.48 467 (100) 0.57 0.52–0.62 6516 (100) 8.02 7.82–8.22
Females 205 (27.1) 0.48 0.41–0.55 78 (22.2) 0.18 0.14–0.22 94 (20.1) 0.22 0.17–0.26 1363 (20.9) 3.17 3.00–3.34
Males 552 (72.9) 1.41 1.29–1.53 274 (77.8) 0.71 0.62–0.79 373 (79.9) 0.97 0.86–1.07 5153 (79.1) 13.50 13.11–13.86
Abbreviations: CI¼confidence interval; HPV¼human papillomavirus.
aSquamous cell carcinomas.
bTonsil (including Waldeyer’s ring) – C09.0, C09.1, C09.8, C09.9 and C14.2.
cBase of tongue and lingual tonsil – C01.9 and C02.4.
dOther oropharynx – C02.8, C10.2, C10.8, C10.9, C14.0 and C14.8.
eComparison cancers (Ryerson et al, 2008) – (a) Oral
tongue – C02.0, C02.1, C02.2, C02.3 and C02.9. (b) Other oral cavity sites – C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C06.0, C06.1, C06.2, C06.8 and
C06.9. (c) Larynx – C32.0, C32.1, C32.2, C32.3, C32.8 and C32.9. (d) Other oropharynx sites – C05.1, C05.2, C05.8, C05.9, C10.0, C10.1 and C10.3.
fRates are per 100000
population and are age standardised to the 2001 Australian population (5 year age groups). (Australian Bureau of Statistics, 2008.)
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tongue and 26.4% were other oropharyngeal cancers, and 28379
cases of comparison site cancers were diagnosed. The age-adjusted
incidence of both potentially HPV-associated and comparison
cancers was consistently three- to fourfold higher among
males than females (Table 1). Potentially HPV-associated orophar-
yngeal cancers were diagnosed at younger ages on average than
comparison site cancers (59.8 vs 64.4 years for males in
2005 (Po0.01) and 63.6 vs 66.9 years for females in 2005
(Po0.01)). The age at diagnosis for potentially HPV-
associated oropharyngeal cancers decreased significantly each
year by 0.06 years (95% CI: 0.01, 0.11) for males with no change for
females. In males, the overall annual decrease in the age at
diagnosis reflected a significant decrease of 0.18 years (95% CI:
0.11, 0.24) for tonsillar cancers and no significant change in age at
diagnosis of cancers of base of tongue or other oropharyngeal sites.
The age at diagnosis for comparison site cancers increased
significantly each year in both males and females (Table 2).
During the period 2000–2005, the age-specific incidence of
potentially HPV-associated cancers was highest among those aged
60–69 years at diagnosis compared with 70–79 years for
comparison site cancers (Figure 1).
The incidence of potentially HPV-associated cancers increased
significantly for both males and females during the study period
with an annual percentage increase of 1.04% (95% CI: 0.40, 1.68%)
for females and 1.42% (95% CI: 1.08, 1.76%) for males. The
increase was greatest for base of tongue for both males and females
with increases of 43% per year. The incidence of comparison site
cancers decreased significantly for males with rates remaining
relatively stable for females (Table 2 and Figure 2). The proportion
of cancers diagnosed each year at potentially HPV-associated
oropharyngeal sites increased from 18.60% in 1982 to 28.70% in
2005 (Po0.01).
Potentially HPV-associated oropharyngeal cancers showed a
general pattern of higher incidence among recent compared with
distant birth cohorts. Among the age groups 45–49 years, 50–54
years and 55–59 years, incidence rates were lowest for the most
distant birth cohorts (cohorts born between 1925 and 1940);
Table 2 Age at diagnosis of oral cavity and oropharyngeal cancers (2005), trends in mean age over time (1982–2005) and changes in age standardised
incidence over time (1982–2005)
a
Cancers diagnosed
in 2005
Trends in age at diagnosis
from 1982 to 2005
Changes in incidence from
1982 to 2005
Sex Cancer site Count
Mean age at
diagnosis
(95% CI)
Percentage change
per calendar
year (95% CI)
b P-value
Percentage change per
calendar
year (95% CI)
c P-value
Males Potentially HPV associated 413 59.8 (58.8–60.9)  0.06 ( 0.11,  0.01) 0.02 1.42 (1.08 to 1.76) o0.01
Tonsil 193 57.4 (56.0–58.9)  0.18 ( 0.24,  0.11) o0.01 1.39 (0.88 to 1.92) o0.01
Base of tongue 125 60.3 (58.5–62.2) 0.02 ( 0.05, 0.09 0.54 3.02 (2.27 to 3.78) o0.01
Other oropharynx 95 64.1 (61.8–66.4) 0.09 ( 0.01, 0.18) 0.06  0.19 ( 0.95 to 0.59) 0.64
Comparison 994 64.4 (63.7–65.2) 0.12 (0.10, 0.15) o0.01  1.69 ( 1.96 to  1.42) o0.01
Females Potentially HPV associated 118 63.6 (61.6–65.6) 0.04 ( 0.07, 0.14) 0.47 1.04 (0.40 to 1.68) o0.01
Tonsil 52 63.1 (60.2–66.1)  0.03 ( 0.17, 0.10) 0.61 0.12 ( 0.95 to 1.19) 0.83
Base of tongue 43 62.9 (59.5–66.3)  0.01 ( 0.15, 0.14) 0.93 3.45 (2.21 to 4.70) o0.01
Other oropharynx 23 65.8 (60.8–70.7) 0.20 (0.02, 0.39) 0.03  0.24 ( 1.57 to 1.10) 0.72
Comparison 324 66.9 (65.4–68.5) 0.07 (0.03, 0.12) o0.01  0.39 ( 0.81 to 0.03) 0.07
Abbreviations: CI¼confidence interval; HPV¼human papillomavirus.
aSquamous cell carcinomas.
bEstimated by linear regression analysis.
cEstimated using generalised linear
models with a logarithmic link function.
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peaked for cohorts born between 1945 and 1955. In contrast, age-
specific incidence rates for comparison cancers showed a general
pattern of decreasing incidence among recent compared with
distant birth cohorts (Figure 3).
DISCUSSION
Within Australia, the incidence of potentially HPV-associated
oropharyngeal cancers increased between 1982 and 2005, and was
more marked within recent birth cohorts. The incidence of
comparison site cancers declined significantly during the same
period, particularly among recent birth cohorts. The proportion of
cancers occurring that are potentially HPV-associated increased
significantly during the study period as a result of both decreasing
incidence of comparison site cancers and increasing incidence of
potentially HPV-associated oropharyngeal cancers. Both poten-
tially HPV-associated oropharyngeal and comparison site cancers
were predominantly diagnosed in males. In addition, the age at
diagnosis for potentially HPV-associated oropharyngeal cancer
declined significantly over time for males, consistent with the
reported younger age for individuals with HPV DNA-positive vs
HPV DNA-negative oral cavity and oropharyngeal cancer (Gillison,
2007; Hong et al, 2010).
Our findings are consistent with previous studies of trends in
oral cavity and oropharyngeal cancers (Shiboski et al, 2005; Sturgis
and Cinciripini, 2007; Chaturvedi et al, 2008; Ryerson et al, 2008),
and further supported by studies that have examined the
proportion of oropharyngeal cancers that is HPV DNA positive.
In Sweden, the proportion of cancer of the base of tongue that was
HPV DNA positive increased from 58% during 1998–2001 to 84%
in 2004–2007 (Attner et al, 2010) and the proportion of tonsillar
cancer that was positive increased from 68% in 2000–2002 to 93%
in 2006–2007 (Nasman et al, 2009). A case series conducted in
Australia showed that the proportion of oropharyngeal cancer
that was positive increased from 19% in 1987–1990 to 66% in
2005–2006 (Hong et al, 2010). In each case, over 80% of the
HPV-DNA-positive cancers contained HPV16.
It is likely that our findings are real effects, because the
procedures for diagnosing, reporting and coding oral cavity and
oropharyngeal cancers have not changed significantly over time
(Chaturvedi et al, 2008). We observed distinct birth cohort effects
for both potentially HPV-associated oropharyngeal cancers and
comparison site cancers, suggesting that the exposures within the
underlying populations have changed over time. The decline in the
incidence of comparison site cancer during the study period and
within birth cohorts may reflect trends in smoking prevalence. In
Australia, smoking prevalence was highest in males during the
1930s and 1940s at over 70% (Scollo and Winstanley, 2008) and has
declined in subsequent years to a prevalence among adults of
about 17% in 2007 (Australian Institute of Health and Welfare,
2008b). Although alcohol is also an established risk factor for oral
cavity cancers (Blot et al, 1988; Franceschi et al, 1990; Hashibe
et al, 2007), alcohol consumption in Australia last century more
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a per capita consumption in those age 15 and over of between
9 and 10l per year (Chikritzhs et al, 2003; Australian Bureau of
Statistics, 2010). Although 83% of Australians are drinkers, almost
10% drink at levels posing a risk of long term harm (Australian
Institute of Health and Welfare, 2008a), but its role in the
incidence of comparison site cancer is unclear (McMichael, 1979).
We hypothesise that changes in sexual behaviour are contribut-
ing to the increasing incidence of potentially HPV-associated
oropharyngeal cancers in recent birth cohorts. Previous studies
have reported associations between sexual risk behaviour and
cancers, which are associated with an increasing number of
lifetime sexual partners (Heck et al, 2010), increasing numbers
of oral sex partners (Gillison et al, 2008; Heck et al, 2010), early age
at sexual debut (Heck et al, 2010) and among men with a history of
same sex sexual contact (Heck et al, 2010). Australian sexual
behaviour data show that the age of sexual debut has declined
significantly from 19 and 18 among 50- to 59-year-old females and
males, respectively, in 2001 to 16 among 16 to19 year old females
and males (de Visser et al, 2003); the number of oral sex partners
has been increasing (Rissel et al, 2003). Our observations of
increased incidence of potentially HPV-associated oropharyngeal
cancers among recent birth cohorts are consistent with this
changing sexual behaviour. However, whether the predominance
of these cancers in males is due to differences in sexual behaviour
or biology is unknown (Marur et al, 2010).
This study has limitations that are relevant to its interpretation.
First, our classification of oral cavity and oropharyngeal cancers as
potentially HPV associated or comparison site was based on
aetiological evidence from previous studies and not on an actual
assessment of the tumour status for the presence of HPV DNA.
Second, we were unable to collect data on tobacco and alcohol use
among cancer cases and as a result, could not analyse the role of
these risk factors. Third, we obtained data that had been collected
and coded by eight different state and territory registries and
collated by the NCSCH, and it is unclear whether each registry
used the same method for handling sub-site cancers. However,
given that they use the IARC and the International Association of
Cancer Registries rules to code cancers, this is unlikely to be a
significant problem (Fritz et al, 2000; IARC, 2004). Finally, some of
our sub-group analyses by specific cancer type and for females
were limited by the small numbers of cancer cases. Nevertheless,
the trends observed for potentially HPV-associated oropharyngeal
cancers were similar between males and females. Further, given
that the prevalence of tobacco smoking among females increased
during the 1960s and 1970s (Scollo and Winstanley, 2008), it will
take some time before any potential decline in comparison site
cancers, similar to that which has been observed in males, is also
observed in females in Australia.
Given the role HPV has in the aetiology of some oral cavity and
oropharyngeal cancers, HPV vaccines may be able to reduce the
incidence of these cancers (Grulich et al, 2010). However, the
natural history of HPV infection in the oral cavity and oropharynx
remains unclear, with varying estimates of prevalence and an
absence of a standardised collection and testing methodology
(D’Souza et al, 2009; Kreimer, 2009; Syrjanen, 2010). If, as
epidemiological data strongly suggests, genital–oral contact is an
important route of HPV16 transmission into the oropharynx, then
a falling exposure to genital HPV infection due to widespread
vaccination may reduce the likelihood of HPV16 transmission, the
risk of subsequent persistence and eventually cancer of the
oropharynx. In addition, there is evidence that IgG antibodies
produced by HPV vaccination transude into the oral cavity,
potentially providing direct protection to vaccines (Rowhani-
Rahbar et al, 2009). Our ability to predict the possible affect of
prophylactic HPV vaccines on oropharyngeal cancers with any
certainty awaits a better understanding of the epidemiology of
HPV infection and its natural history in the oropharynx.
We found that while the incidence and proportion of
comparison site cancers decreased during the period 1982–2005,
the incidence and the proportion of potentially HPV-associated
oropharyngeal cancers increased, particularly among recent birth
cohorts. This increase may be attributable in part to changing
sexual behaviours. Given that, it is likely that the incidence of
HPV-associated oral cavity and oropharyngeal cancers will
continue to increase, based on observed trends, the current HPV
vaccination programme in Australia for females aged 12 to
13 years introduced in 2007 (Shefer et al, 2008) may have an
affect on the future incidence of these cancers. The extent of this
needs to be carefully modeled so that we can estimate the potential
benefit from any further expansion of the current HPV vaccination
programmes, including extending the programme to males.
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